Valuation: bioMérieux

Capitalization 11.25B 13.04B 10.15B 9.74B 17.76B 1,199B 18.59B 120B 48.08B 575B 48.95B 47.91B 2,056B P/E ratio 2025
33x
P/E ratio 2026 * 20.4x
Enterprise value 10.93B 12.67B 9.86B 9.46B 17.26B 1,165B 18.06B 117B 46.71B 558B 47.56B 46.55B 1,997B EV / Sales 2025
3.2x
EV / Sales 2026 * 2.5x
Free-Float
36.04%
Yield 2025 *
0.97%
Yield 2026 * 1.15%
1 day+0.16%
1 week-4.60%
Current month-4.60%
1 month+0.63%
3 months-8.53%
6 months-16.24%
Current year-13.51%
1 week 94.35
Extreme 94.35
101.5
1 month 91.85
Extreme 91.85
102.1
Current year 91.85
Extreme 91.85
116.1
1 year 91.85
Extreme 91.85
128.3
3 years 84.54
Extreme 84.54
128.3
5 years 77.48
Extreme 77.48
133.2
10 years 32.39
Extreme 32.39
144.8
Manager TitleAgeSince
Chief Executive Officer 54 30/06/2023
Director of Finance/CFO 49 28/02/2018
Chief Tech/Sci/R&D Officer - 01/01/2024
Director TitleAgeSince
Chairman 76 31/12/2013
Chairman 52 14/12/2017
Director/Board Member 65 31/12/2004
Change 5d. change 1-year change 3-years change Capi.($)
+0.16%-4.60%-16.68%+2.34% 13B
-0.94%-2.01%+129.06%+204.38% 12.14B
+4.83%+4.97%-10.26%-8.25% 5.93B
-1.69%-5.76% - - 5.43B
-4.76%-2.56%-27.18%-0.01% 4.93B
+0.35%-3.15%-27.71%-38.81% 4.29B
-2.45%+12.04%+17.97%+1.09% 3.06B
+1.74%-3.26%-16.19%-44.34% 2.85B
-3.72%-9.07%+82.74%-56.72% 2.76B
+10.00%+13.02%+47.85%+69.78% 1.86B
Average +0.36%+1.03%+19.95%+14.38% 5.63B
Weighted average by Cap. -0.10%-0.33%+26.82%+42.24%

Financials

2025 2026 *
Net sales 4.1B 4.76B 3.7B 3.55B 6.48B 437B 6.78B 43.77B 17.54B 210B 17.85B 17.47B 750B 4.26B 4.94B 3.85B 3.69B 6.73B 454B 7.04B 45.46B 18.21B 218B 18.54B 18.15B 779B
Net income 456M 528M 411M 395M 719M 48.55B 753M 4.86B 1.95B 23.28B 1.98B 1.94B 83.27B 547M 634M 494M 474M 863M 58.27B 904M 5.83B 2.34B 27.94B 2.38B 2.33B 99.94B
Net Debt -320M -371M -289M -277M -505M -34.08B -528M -3.41B -1.37B -16.34B -1.39B -1.36B -58.45B -586M -679M -529M -507M -925M -62.43B -968M -6.25B -2.5B -29.94B -2.55B -2.5B -107B
Logo bioMérieux
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.8%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.2%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (31.9%), North America (45%), Asia/Pacific (16,5%) and Latin America (6.6%).
Employees
14,451
Date Price Change Volume
06/03/26 95.40 +0.16% 83,131
05/03/26 95.25 -2.91% 93,720
04/03/26 98.10 -0.71% 133,041
03/03/26 98.80 -2.18% 165,271
02/03/26 101.00 +1.00% 243,844
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
95.25EUR
Average target price
117.88EUR
Spread / Average Target
+23.76%

Quarterly revenue - Rate of surprise